

# NEUROTHERAPEUTICS SEMINAR SERIES



TEXAS A&M HEALTH

Institute of Pharmacology  
and Neurotherapeutics

## Translational Therapy Development Programs at the National Institute of Neurological Disorders and Stroke (NINDS)

**Monday, November 25, 2024**

**HSC Bryan Campus/MREB 2 Room 1403**

**12:00 - 1:00 PM CT**

**Lunch Provided--- Q&A session and networking opportunity**

**Join via Zoom  Meeting ID: 942 5772 9124 Passcode: 052206**

### Dr. Brian Klein, Ph.D.

*Program Director, Epilepsy Therapy Screening Program, Division of Translational Research, National Institute of Neurological Disorders and Stroke, Rockville, MD.*

Dr. Klein is a Program Director in the Division of Translational Research at the National Institute of Neurological Disorders and Stroke (NINDS) and leads the Epilepsy Therapy Screening Program (ETSP). He also manages a preclinical epilepsy grant portfolio in the Division of Neuroscience at NINDS. Prior to joining NINDS in 2015, he served as a Program Director at the National Cancer Institute (NCI) responsible for preclinical evaluation of experimental agents enrolled in the PREVENT Cancer Drug Development Program. He previously held industry positions at Johnson & Johnson Pharmaceutical Research & Development as preclinical pharmacologist for three antiepileptic drug development programs and at two biotech companies focused on development of modified neuropeptide and venom-based peptide therapies for the treatment of epilepsy and pain. Dr. Klein received a Ph.D. in Pharmacology and Toxicology from the University of Utah where his research characterized mouse seizure models utilized by the Anticonvulsant Drug Development Program.



Dr. Klein

**Host: Dr. Samba Reddy**  
**sambareddy@tamu.edu**

**For more info, contact Dr. Sreevidhya Ramakrishnan at [sreevidh@tamu.edu](mailto:sreevidh@tamu.edu)**

IPN Website:

